Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Publications (10 of 24) Show all publications
Lindberg, A., Hellberg, L., Grandon, A., Yu, H., Thurfjell, V., Wåhlén, E., . . . Strell, C. (2026). In situ mapping of activated PDGFRβ defines a prognostic discrepancy between histological subtypes of NSCLC. Cell Communication and Signaling, 24, Article ID 55.
Open this publication in new window or tab >>In situ mapping of activated PDGFRβ defines a prognostic discrepancy between histological subtypes of NSCLC
Show others...
2026 (English)In: Cell Communication and Signaling, E-ISSN 1478-811X, Vol. 24, article id 55Article in journal (Refereed) Published
Abstract [en]

Background: Increased stromal Platelet-derived growth factor receptor beta (PDGFRβ) expression is a hallmark of the desmoplastic tissue reaction in cancer and marks subsets of cancer-associated fibroblasts, pericytes, and smooth muscle cells. However, its functional status in situ has been anticipated from static expression measures, which cannot determine whether high receptor abundance reflects active signaling.

Methods: We established two second-generation proximity ligation assays (PLAs) to quantify PDGFRβ activation in the in situ environment of human lung cancer by detecting either phosphorylated PDGFRβ or its interaction with the adaptor protein Grb2. The immunofluorescence-based assays were applied to tissue-microarrays including diagnostic samples from over 600 non-small cell lung cancer (NSCLC) patients.

Results: In lung cancer tissue, activation scores correlated with PDGFRβ expression but revealed a more nuanced receptor status, indicating variable activation despite similar expression levels. Higher PDGFRβ activation was associated with increased recurrence risk exclusively in squamous cell carcinoma, a finding not captured by conventional immunohistochemistry. This activation was accompanied by a specific stromal profile enriched for LRRC15- and FAP-positive cells, a pattern absent in adenocarcinomas.

Conclusion: PDGFRβ activation status provides functional information beyond receptor expression, uncovering clinically relevant, otherwise overlooked, stromal phenotypes. The approach illustrates the diagnostic potential of functional protein assays in the era of precision medicine.

Place, publisher, year, edition, pages
Springer Nature, 2026
National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-578638 (URN)10.1186/s12964-026-02651-3 (DOI)001674078200001 ()41540507 (PubMedID)2-s2.0-105028893909 (Scopus ID)
Funder
Uppsala UniversitySwedish Cancer SocietySwedish Research CouncilSjöberg Foundation
Available from: 2026-02-06 Created: 2026-02-06 Last updated: 2026-02-06Bibliographically approved
Nwadozi, E., Strell, C., Nordling, S., Lindberg, A., Backman, M., Daller Cosmen, P., . . . Claesson-Welsh, L. (2026). Vascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy. Cancer Letters, 658, Article ID 218728.
Open this publication in new window or tab >>Vascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy
Show others...
2026 (English)In: Cancer Letters, ISSN 0304-3835, E-ISSN 1872-7980, Vol. 658, article id 218728Article in journal (Refereed) Published
Abstract [en]

Leaky blood vessels are a hallmark of solid tumors. However, the molecular mechanisms and clinical implications of vascular leakage in human cancer remain unexplored. Here, we identified fibrinopeptide-A (FpA) as a robust in-situ marker of vascular leakage, analyzing diagnostic specimens from two non-small cell lung cancer (NSCLC) cohorts (N = 327 and N = 200). Mechanistically, FpA+ staining localized to discrete stromal niches characterized by increased endothelial VEGF receptor-2 phosphorylation, elevated VEGFA production by tumor cells and loss of the endothelial tyrosine phosphatase PTPRB. Immune profiling revealed reduced density of mature dendritic cells and granzyme B-expressing cytotoxic T cells in tumors with high-leakage. This leakage-associated immunosuppression was linked to the presence of tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD). However, compared to low-leakage, TLS in high-leakage tumors were enriched in regulatory T cells and conferred no survival advantage. Patients with high vascular leakage exhibited a reduced overall survival. Moreover, in a separate immunotherapy cohort (N = 64), high-leakage was associated with poor response to anti-PD-1/PD-L1 treatment. This study establishes vascular leakage as an important prognostic factor in NSCLC, and provides mechanistic understanding and a methodological framework to stratify NSCLC patients with regard to responsiveness to immunotherapy.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
Non-small cell lung cancer, Vascular leakage, Fibrinopeptide A, VEPTP, Tertiary lymphoid structures, Immunotherapy response
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-595809 (URN)10.1016/j.canlet.2026.218728 (DOI)001839903800001 ()42486347 (PubMedID)2-s2.0-105046045859 (Scopus ID)
Funder
Swedish Cancer Society, 25 4398 Pj 01 HSwedish Cancer Society, 21-1790Swedish Cancer Society, 211749PjSwedish Research Council, 2025-02853Swedish Research Council, 2022-01151Knut and Alice Wallenberg Foundation, KAW 2023.0212
Note

De två sista författarna delar sistaförfattarskapet

Available from: 2026-08-19 Created: 2026-08-19 Last updated: 2026-08-19Bibliographically approved
Lindberg, A., Muhl, L., Yu, H., Hellberg, L., Artursson, R., Friedrich, J., . . . Strell, C. (2025). In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC. Journal of Thoracic Oncology, 20(5), 625-640
Open this publication in new window or tab >>In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC
Show others...
2025 (English)In: Journal of Thoracic Oncology, ISSN 1556-0864, E-ISSN 1556-1380, Vol. 20, no 5, p. 625-640Article in journal (Refereed) Published
Abstract [en]

Background

Immune checkpoint inhibitors (ICIs) have transformed lung cancer treatment, yet their effectiveness appears restricted to certain patient subsets. Current clinical stratification based on PD-L1 expression offers limited predictive value. Given the mechanism of action, directly detecting spatial PD1–PD-L1 interactions might yield more precise insights into immune responses and treatment outcomes.

Methods

We applied a second-generation in situ proximity ligation assay (PLA) to detect PD1–PD-L1 interactions in diagnostic tissue samples from 16 different cancer types, a tissue microarray from 352 surgically resected early-stage non-small cell lung cancer (NSCLC) patients, and finally diagnostic biopsies from 242 advanced NSCLC patients with and without ICI treatment. RNAseq analysis was used to identify potential resistance mechanisms.

Results

In the early-stage NSCLC, only about half of the cases with detectable PD-L1 and PD1 expression showed PD1–PD-L1 interactions, with significantly lower levels in EGFR-mutated tumors. Interaction levels varied across cancer types, aligning with reported ICI response rates. In ICI-treated NSCLC patients, higher PD1–PD-L1 interactions were linked to complete responses and longer survival, outperforming standard PD-L1 expression assays. Patients who, despite high PD1–PD-L1 interactions, did not respond to ICIs, showed additional expression of stromal immune mediators (EOMES, HAVCR1/TIM-1, JAML, FCRL1).

Conclusion

Our study proposes a diagnostic shift from static biomarker quantification to assessing active immune pathways, providing more precise ICI treatment. This functional concept applies to tiny lung biopsies and can be used to further immune checkpoints. Accordingly, our results indicate concerted ICI resistance mechanisms, highlighting a need for combination diagnostics and therapies.

Place, publisher, year, edition, pages
Elsevier, 2025
Keywords
Immune checkpoint inhibitor (ICI), Programmed death-ligand 1 (PD-L1), Programmed cell death protein 1 (PD1), non-small cell lung cancer (NSCLC), Proximity ligation assay (PLA)
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-546466 (URN)10.1016/j.jtho.2024.12.026 (DOI)001504694800008 ()39743139 (PubMedID)2-s2.0-85216903906 (Scopus ID)
Funder
Swedish Research Council, 2022-01151Sjöberg FoundationSwedish Cancer Society, 21149PJSwedish Cancer Society, 211790PJSwedish Research Council, 2021-02693Insamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroSwedish Cancer Society, 201368PjDr. Margaretha Nilssons Stiftelse för Medicinsk forskning
Note

Patrick Micke och Carina Strell delar sistaförfattarskapet

Available from: 2025-01-09 Created: 2025-01-09 Last updated: 2026-11-06Bibliographically approved
Elfving, H., Yu, H., Kassete Fessehatsio, K., Brunnström, H., Botling, J., Gulyas, M., . . . Micke, P. (2025). Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.. Cellular Oncology, 48, 801-808
Open this publication in new window or tab >>Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.
Show others...
2025 (English)In: Cellular Oncology, ISSN 2211-3428, E-ISSN 2211-3436, Vol. 48, p. 801-808Article in journal (Refereed) Published
Abstract [en]

Introduction

Tertiary lymphoid structures (TLS) are lymphocyte aggregates resembling secondary lymphoid organs and are pivotal in cancer immunity. The ambiguous morphological definition of TLS makes it challenging to ascertain their clinical impact on patient survival and response to immunotherapy.

Objectives

This study aimed to characterize TLS in hematoxylin-eosin tissue sections from lung cancer patients, assessing their occurrence in relation to the local immune environment, mutational background, and patient outcome.

Methods

Two pathologists evaluated one whole tissue section from resection specimens of 680 NSCLC patients. TLS were spatially quantified within the tumor area or periphery and further categorized based on the presence of germinal centers (mature TLS). Metrics were integrated with immune cell counts, genomic and transcriptomic data, and correlated with clinical parameters.

Results

TLS were present in 86% of 536 evaluable cases, predominantly in the tumor periphery, with a median of eight TLS per case. Mature TLS were found in 24% of cases. TLS presence correlated positively with increased plasma cell (CD138+) and lymphocytic cell (CD3+, CD8+, FOXP3+) infiltration. Tumors with higher tumor mutational burden exhibited higher numbers of peripheral TLS. The overall TLS quantity was independently associated with improved patient survival, irrespective of TLS maturation status. This prognostic association held true for peripheral TLS but not for tumor TLS.

Conclusion

TLS in NSCLC is common and their correlation with a specific immune phenotype suggests biological relevance in the local immune reaction. The prognostic significance of this scoring system on routine hematoxylin-eosin sections has the potential to augment diagnostic algorithms for NSCLC patients.

Place, publisher, year, edition, pages
Springer, 2025
Keywords
Immunotherapy, Tumor microenvironment, Prognosis, Lymphocytes, Immune microenvironment
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-517152 (URN)10.1007/s13402-025-01052-x (DOI)001435524700001 ()40029549 (PubMedID)
Available from: 2023-12-04 Created: 2023-12-04 Last updated: 2025-09-10Bibliographically approved
Yu, H., Magoulopoulou, A., Amini, R.-M., Chatzinikolaou, M. P., Horie, M., Lindberg, A., . . . Micke, P. (2025). Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 13(8), Article ID e012089.
Open this publication in new window or tab >>Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer
Show others...
2025 (English)In: Journal for ImmunoTherapy of Cancer, E-ISSN 2051-1426, Vol. 13, no 8, article id e012089Article in journal (Refereed) Published
Abstract [en]

Background T-cell activation and clonal expansion are essential to effective immunotherapy responses in non-small cell lung cancer (NSCLC). The distribution of T-cell clones may offer insights into immunogenic mechanisms and imply potential prognostic and predictive information.

Methods We analyzed alpha/beta T-cell receptor (TCR) clonality using RNA-sequencing of bulk frozen tumor tissue from 182 patients with NSCLC. The data was integrated with molecular and clinical characteristics, extensive in situ imaging, and spatial sequencing of the tumor immune microenvironment. TCR clonality was also determined in an independent cohort of nine patients with immune checkpoint-treated NSCLC.

Results TCR clonality (Gini index) patterns ranged from high T-cell clone diversity with high evenness (low Gini index) to clonal dominance with low evenness (high Gini index). Generally, TCR clonality in cancer was lower than in matched normal lung parenchyma distant from the tumor (p=0.021). The TCR clonality distribution between adenocarcinoma and squamous cell carcinoma was similar; however, smokers showed a higher Gini index. While in the operated patient with NSCLC cohort, TCR clonality was not prognostic, in an immune checkpoint inhibitor-treated cohort, high TCR clonality was associated with better therapy response (p=0.016) and prolonged survival (p=0.003, median survival 13.8 vs 2.9 months). On the genomic level, a higher Gini index correlated strongly with a lower frequency of epidermal growth factor receptor (EGFR) and adenomatous polypsis coli (APC) gene mutations, but a higher frequency of P53 mutations, and a higher tumor mutation burden. In-depth characterization of the tumor tissue revealed that high TCR clonality was associated with an activated, inflamed tumor phenotype (PRF1, GZMA, GZMB, INFG) with exhaustion signatures (LAG3, TIGIT, IDO1, PD-1, PD-L1). Correspondingly, PD-1+, CD3+, CD8A+, CD163+, and CD138+immune cells infiltrated cancer tissue with high TCR clonality. In situ sequencing recovered single dominant T-cell clones within the patient tumor tissue, which were predominantly of the CD8 subtype and localized closer to tumor cells.

Conclusion Our robust analysis pipeline characterized diverse TCR repertoires linked to distinct genotypes and immunologic tumor phenotypes. The spatial clustering of expanded T-cell clones and their association with immunological activation underscores a functional, clinically relevant immune response, particularly in patients with NSCLC treated with checkpoint inhibitors.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2025
Keywords
T cell Receptor - TCR, Immune Checkpoint Inhibitor, T cell, Lung Cancer, Clonality
National Category
Cancer and Oncology Immunology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-568270 (URN)10.1136/jitc-2025-012089 (DOI)001564898200001 ()40866291 (PubMedID)2-s2.0-105014547317 (Scopus ID)
Funder
Swedish Cancer Society
Note

Carina Strell och Patrick Micke delar sistaförfattarskapet

Available from: 2025-10-02 Created: 2025-10-02 Last updated: 2026-04-10Bibliographically approved
Elfving, H., Thurfjell, V., Mattsson, J. S., Backman, M., Strell, C. & Micke, P. (2024). Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies. Archives of Pathology & Laboratory Medicine, 148(1), e18-e24
Open this publication in new window or tab >>Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies
Show others...
2024 (English)In: Archives of Pathology & Laboratory Medicine, ISSN 0003-9985, E-ISSN 1543-2165, Vol. 148, no 1, p. e18-e24Article in journal (Refereed) Published
Abstract [en]

Context.—The immune microenvironment is involved in fundamental aspects of tumorigenesis, and immune scores are now being developed for clinical diagnostics. Objective.—To evaluate how well small diagnostic biopsies and tissue microarrays (TMAs) reflect immune cell infiltration compared to the whole tumor slide, in tissue from patients with non–small cell lung cancer. Design.—A TMA was constructed comprising tissue from surgical resection specimens of 58 patients with non–small cell lung cancer, with available preoperative biopsy material. Whole sections, biopsies, and TMA were stained for the pan-T lymphocyte marker CD3 to determine densities of tumor-infiltrating lymphocytes. Immune cell infiltration was assessed semiquantitatively as well as objectively with a microscopic grid count. For 19 of the cases, RNA sequencing data were available. Results.—The semiquantitative comparison of immune cell infiltration between the whole section and the biopsy displayed fair agreement (intraclass correlation coefficient [ICC], 0.29; P ¼ .01; CI, 0.03–0.51). In contrast, the TMA showed substantial agreement compared with the whole slide (ICC, 0.64; P , .001; CI, 0.39–0.79). The grid-based method did not enhance the agreement between the different tissue materials. The comparison of CD3 RNA sequencing data with CD3 cell annotations confirmed the poor representativity of biopsies as well as the stronger correlation for the TMA cores. Conclusions.—Although overall lymphocyte infiltration is relatively well represented on TMAs, the representativity in diagnostic lung cancer biopsies is poor. This finding challenges the concept of using biopsies to establish immune scores as prognostic or predictive biomarkers for diagnostic applications.

Place, publisher, year, edition, pages
Archives of Pathology and Laboratory Medicine, 2024
Keywords
lung cancer, immunotherapy, checkpoint inhibitors, tumor microenvironment, prognosis, PD-L1, lymphocytes
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-517148 (URN)10.5858/arpa.2022-0327-oa (DOI)001137617500012 ()
Available from: 2023-12-04 Created: 2023-12-04 Last updated: 2026-10-27Bibliographically approved
Mezheyeuski, A., Backman, M., Mattsson, J. S., Martin-Bernabe, A., Larsson, C., Hrynchyk, I., . . . Sjöblom, T. (2023). An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. eBioMedicine, 88, Article ID 104452.
Open this publication in new window or tab >>An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers
Show others...
2023 (English)In: eBioMedicine, E-ISSN 2352-3964, Vol. 88, article id 104452Article in journal (Refereed) Published
Abstract [en]

Background: Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve the accuracy in predicting disease progression.

Methods: Through a multiplex in situ analysis we evaluated 15 immune cell classes in 1481 tumour samples. Single-cell and bulk RNAseq data sets were used for functional analysis and validation of prognostic and predictive associations.

Findings: By combining the prognostic information of anti-tumoural CD8+ lymphocytes and tumour supportive CD68+CD163+ macrophages in colorectal cancer we generated a signature of immune activation (SIA). The prognostic impact of SIA was independent of conventional parameters and comparable with the state-of-art immune score. The SIA was also associated with patient survival in oesophageal adenocarcinoma, bladder cancer, lung adenocarcinoma and melanoma, but not in endometrial, ovarian and squamous cell lung carcinoma. We identified CD68+CD163+ macrophages as the major producers of complement C1q, which could serve as a surrogate marker of this macrophage subset. Consequently, the RNA-based version of SIA (ratio of CD8A to C1QA) was predictive for survival in independent RNAseq data sets from these six cancer types. Finally, the CD8A/C1QA mRNA ratio was also predictive for the response to checkpoint inhibitor therapy.

Interpretation: Our findings extend current concepts to procure prognostic information from the tumour immune microenvironment and provide an immune activation signature with high clinical potential in common human cancer types.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Tumour immunology, Macrophages, Immunoscore
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-501100 (URN)10.1016/j.ebiom.2023.104452 (DOI)000963637000001 ()36724681 (PubMedID)2-s2.0-85147117975 (Scopus ID)
Funder
Swedish Cancer Society, CAN 2018/772Swedish Cancer Society, CAN 2019/447Swedish Cancer Society, CAN 2018/816Region UppsalaInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroErik, Karin och Gösta Selanders FoundationP.O. Zetterling Foundation
Note

Patrick Micke och Tobias Sjöblom delar sistaförfattarskapet

Available from: 2023-05-03 Created: 2023-05-03 Last updated: 2026-04-10Bibliographically approved
Hikmet Noraddin, F., Rassy, M., Backman, M., Méar, L., Mattsson, J. S., Djureinovic, D., . . . Lindskog, C. (2023). Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. Molecular Oncology, 17(12), 2603-2617
Open this publication in new window or tab >>Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer
Show others...
2023 (English)In: Molecular Oncology, ISSN 1574-7891, E-ISSN 1878-0261, Vol. 17, no 12, p. 2603-2617Article in journal (Refereed) Published
Abstract [en]

The antigenic repertoire of tumors is critical for successful anti-cancer immune response and the efficacy of immunotherapy. Cancer-testis antigens (CTAs) are targets of humoral and cellular immune reactions. We aimed to characterize CTA expression in non-small cell lung cancer (NSCLC) in the context of the immune microenvironment. Of 90 CTAs validated by RNA sequencing, eight CTAs (DPEP3, EZHIP, MAGEA4, MAGEB2, MAGEC2, PAGE1, PRAME, and TKTL1) were selected for immunohistochemical profiling in cancer tissues from 328 NSCLC patients. CTA expression was compared with immune cell densities in the tumor environment and with genomic, transcriptomic, and clinical data. Most NSCLC cases (79%) expressed at least one of the analyzed CTAs, and CTA protein expression correlated generally with RNA expression. CTA profiles were associated with immune profiles: high MAGEA4 expression was related to M2 macrophages (CD163) and regulatory T cells (FOXP3), low MAGEA4 was associated with T cells (CD3), and high EZHIP was associated with plasma cell infiltration (adj. P-value < 0.05). None of the CTAs correlated with clinical outcomes. The current study provides a comprehensive evaluation of CTAs and suggests that their association with immune cells may indicate in situ immunogenic effects. The findings support the rationale to harness CTAs as targets for immunotherapy.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
cancer-testis antigens, immune phenotype, immune-oncology, non-small cell lung cancer
National Category
Cancer and Oncology Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-522496 (URN)10.1002/1878-0261.13474 (DOI)001020469000001 ()37341056 (PubMedID)2-s2.0-85163033315 (Scopus ID)
Funder
Swedish Cancer Society, 21 1790Knut and Alice Wallenberg Foundation, 2015.0344Sjöberg Foundation
Note

Patrick Micke och Cecilia Lindskog delar sistaförfattarskapet

Available from: 2024-02-07 Created: 2024-02-07 Last updated: 2026-04-10Bibliographically approved
Pellinen, T., Paavolainen, L., Martín-Bernabé, A., Papatella Araujo, R., Strell, C., Mezheyeuski, A., . . . Östman, A. (2023). Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features. Journal of the National Cancer Institute, 115(1), 71-82
Open this publication in new window or tab >>Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features
Show others...
2023 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 115, no 1, p. 71-82Article in journal (Refereed) Published
Abstract [en]

Background

Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous mesenchymal cells that interact with malignant cells and immune cells and confer anti- and protumorigenic functions. Prior in situ profiling studies of human CAFs have largely relied on scoring single markers, thus presenting a limited view of their molecular complexity. Our objective was to study the complex spatial tumor microenvironment of non-small cell lung cancer (NSCLC) with multiple CAF biomarkers, identify novel CAF subsets, and explore their associations with patient outcome.

Methods

Multiplex fluorescence immunohistochemistry was employed to spatially profile the CAF landscape in 2 population-based NSCLC cohorts (n = 636) using antibodies against 4 fibroblast markers: platelet-derived growth factor receptor-alpha (PDGFRA) and -beta (PDGFRB), fibroblast activation protein (FAP), and alpha-smooth muscle actin (αSMA). The CAF subsets were analyzed for their correlations with mutations, immune characteristics, and clinical variables as well as overall survival.

Results

Two CAF subsets, CAF7 (PDGFRA-/PDGFRB+/FAP+/αSMA+) and CAF13 (PDGFRA+/PDGFRB+/FAP-/αSMA+), showed statistically significant but opposite associations with tumor histology, driver mutations (tumor protein p53 [TP53] and epidermal growth factor receptor [EGFR]), immune features (programmed death-ligand 1 and CD163), and prognosis. In patients with early stage tumors (pathological tumor-node-metastasis IA-IB), CAF7 and CAF13 acted as independent prognostic factors.

Conclusions

Multimarker-defined CAF subsets were identified through high-content spatial profiling. The robust associations of CAFs with driver mutations, immune features, and outcome suggest CAFs as essential factors in NSCLC progression and warrant further studies to explore their potential as biomarkers or therapeutic targets. This study also highlights multiplex fluorescence immunohistochemistry–based CAF profiling as a powerful tool for the discovery of clinically relevant CAF subsets.

Place, publisher, year, edition, pages
Oxford University Press, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-492026 (URN)10.1093/jnci/djac178 (DOI)000867162300001 ()36083003 (PubMedID)2-s2.0-85151506005 (Scopus ID)
Funder
Swedish Cancer SocietySwedish Research CouncilInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroSjöberg Foundation
Note

Patrick Micke och Arne Östman delar på sistaförfattarskapet

Available from: 2022-12-30 Created: 2022-12-30 Last updated: 2026-04-10Bibliographically approved
Backman, M., Strell, C., Lindberg, A., Mattsson, J. S. M., Elfving, H., Brunnström, H., . . . Micke, P. (2023). Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer. European Journal of Cancer, 185, 40-52
Open this publication in new window or tab >>Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer
Show others...
2023 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 185, p. 40-52Article in journal (Refereed) Published
Abstract [en]

Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response to therapy. We aimed to comprehensively characterise the spatial im-mune phenotypes in the mutational and clinicopathological background of non-small cell lung cancer (NSCLC).

Methods: We established a multiplexed fluorescence imaging pipeline to spatially quantify 13 immune cell subsets in 359 NSCLC cases: CD4 effector cells (CD4-Eff), CD4 regulatory cells (CD4-Treg), CD8 effector cells (CD8-Eff), CD8 regulatory cells (CD8-Treg), B-cells, natural killer cells, natural killer T-cells, M1 macrophages (M1), CD163 thorn myeloid cells (CD163), M2 macrophages (M2), immature dendritic cells (iDCs), mature dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs).

Results: CD4-Eff cells, CD8-Eff cells and M1 macrophages were the most abundant immune cells invading the tumour cell compartment and indicated a patient group with a favourable prognosis in the cluster analysis. Likewise, single densities of lymphocytic subsets (CD4-Eff, CD4-Treg, CD8-Treg, B-cells and pDCs) were independently associated with longer survival. However, when these immune cells were located close to CD8-Treg cells, the favourable impact was attenuated. In the multivariable Cox regression model, including cell densities and distances, the densities of M1 and CD163 cells and distances between cells (CD8-Treg-B-cells, CD8-Eff-cancer cells and B-cells-CD4-Treg) demonstrated positive prognostic impact, whereas short M2-M1 distances were prognostically unfavourable.

Conclusion: We present a unique spatial profile of the in situ immune cell landscape in NSCLC as a publicly available data set. Cell densities and cell distances contribute independently to prognostic information on clinical outcomes, suggesting that spatial information is crucial for diagnostic use.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Immune cell infiltration, Multiplex imaging, Checkpoint therapy, Tumour microenvironment, Lung cancer, NSCLC
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-502648 (URN)10.1016/j.ejca.2023.02.012 (DOI)000959970600001 ()36963351 (PubMedID)
Funder
Swedish Cancer SocietySjöberg FoundationInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroErik, Karin och Gösta Selanders Foundation
Note

De två sista författarna delar sistaförfattarskapet

Available from: 2023-05-31 Created: 2023-05-31 Last updated: 2024-03-06Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-8804-1012

Search in DiVA

Show all publications